Darling Ingredients' Rousselot Secures US Patent for Blood Glucose Regulating Collagen Peptide
DAR has more than doubled off its 52-week low of $29.15.
Summary
Darling Ingredients' health brand, Rousselot, has been granted a U.S. patent for its Nextida GC collagen peptide composition, designed to support blood glucose regulation. This patent protects key intellectual property for a specialized health ingredient, strengthening Rousselot's product portfolio and market differentiation within the growing health and wellness sector. It represents a positive step in the company's product innovation efforts.
At the time of this announcement, DAR was trading at $61.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $29.15 to $66.02. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.